Adagene Inc.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Adagene
Pharmaceutical Preparations, SIC 2834
Adagene Inc. is a clinical-stage biotechnology company that discovers and develops antibody-based cancer immunotherapies using computational biology. The company utilizes proprietary antibody platforms, including its Dynamic Precision Library, to engineer masked and empowered antibodies such as NEObodies, SAFEbodies, and POWERbodies. Its product pipeline includes clinical candidates like ADG126, an anti-CTLA-4 therapy undergoing clinical trials for solid tumors such as colorectal cancer, alongside earlier-stage candidates including ADG206, ADG138, and ADG116. Adagene collaborates with and out-licenses technologies to global pharmaceutical and biotechnology partners, academic institutions, and healthcare organizations.
The company maintains an international footprint with research, development, and subsidiary entities across China, the United States, Australia, Singapore, and Switzerland. Adagene conducts research and operations through facilities in San Diego, California, and Suzhou, China, with a registered office in the Cayman Islands. Its corporate headquarters is located in Suzhou, China.
Summary of the business section of Adagene's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Adagene Inc.
- Founded
- 2011
- Headquarters
- Jiangsu, F4
- Address
- 4f, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park 00000
- Phone
- 86-512-87773632
- Website
- adagene.com
- Employees
- 128, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- E9
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers Zhong TianLLP, Shanghai, the Peoples Republic of China
Stock & identifiers
- Ticker
- ADAG
- Exchange
- Nasdaq
- IPO date
- Feb 10, 2021
- Shares outstanding
- 59M, Dec 31, 2025
- Filer category
- Accelerated filer<br>Emerging growth company
- SEC CIK
- 1818838
- CUSIP
- 005329107
- ISIN
- US0053291078
- LEI
- 875500IY38EWGFPSEV72
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Man Kin Tam | Chief Financial Officer, Director | 12,000 |
| Peter Luo | Chief Executive Officer, Director | 194,556 |
| Mickael Yannick Chane-Du | Chief Strategy Officer | 467,525 |
| Qinghai Zhao | Chief Manufacturing Officer | 37,500 |
| Chunfang Gu | Executive Director of Finance | 7,045 |
| Ling Zhou | ED of Human Resources | 2,969 |
| Cuong V. Do | Director | 2,000 |
| Andy Yiu Leung Cheung | Director | – |
| Li Zhu | Director | – |
| Ulf Grawunder | Director | 25,000 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 128 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 10, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 3, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |